Get started

Signalprovider

DXY- Start of correction?In my previous analysis of the DXY, I mentioned that the index might begin a correction after more than three months of upward movement and a 10% increase. Yesterday, the market opened with a downside gap and broke below the rising trendline that had been supporting the price since the 100 mark. This suggests that 110 could now serve as a local top. As long as the price remains below this level, shorting the USD currency could present a viable trading opportunity. I am currently looking for buying opportunities in currency pairs such as EUR/USD, GBP/USD, AUD/USD, and NZD/USD.
TVC:DXYShort
by Mihai_Iacob
COTTON: Potential Sell from Resistance ZoneFOREXCOM:COTTON is nearing a significant resistance level that has previously acted as a ceiling for bullish momentum. The current upward move into this zone suggests potential selling opportunities if rejection signals appear. If bearish patterns such as long upper wicks or bearish engulfing candles emerge, I anticipate a move toward 6,818.0. Traders should wait for clear confirmation before initiating short positions. If you have anything to add or a different perspective, I’d love to hear from you in the comments!
FOREXCOM:COTTONShort
by DanieIM
AUDSGD: Buy Setup at Key Support ZoneOANDA:AUDSGD is near a significant support zone, which has historically been a turning point for bullish moves. The recent bearish pressure brings the price into this critical area, creating a potential buying opportunity. If bullish signals emerge, such as strong buying volume or bullish candlestick patterns, I expect the price to move toward 0.86163, aligning with the overall market structure. However, a break below this support would invalidate the bullish bias and could lead to further declines. Traders should be patient and wait for confirmation of bullish strength before entering long positions.
Long
by DanieIM
1
GBPNZD: Sell Opportunity After Support BreakOANDA:GBPNZD has broken a key support zone signaling a potential increase in bearish momentum. The price is currently retesting this broken support, which now serves as resistance. If sellers confirm resistance at this level, I expect the price to move downward toward 2.15600, aligning with the bearish trend. On the other hand, a failure to hold resistance could indicate a bullish shift. Traders should watch for bearish confirmation signals, such as bearish engulfing candles or strong selling volume, before entering short positions.
Short
by DanieIM
1
Silver could rise above 32 (1500+ pips target)In my previous analysis on OANDA:XAGUSD , I noted that the lack of bearish continuation following the break below the 30 level suggested a high likelihood of a false breakout. I anticipated that the price would most likely reverse to the upside, and this scenario has played out as expected. After breaking back above the 30 level and successfully retesting it, XAG/USD is now holding steadily above this important support. Additionally, the price has broken out of the falling wedge pattern by moving above the descending trendline. The morning star candlestick formation observed two days ago further reinforces the bullish outlook. Adding to the positive sentiment, a strong close today could result in a continuation pin bar on the weekly chart, further supporting upward momentum. In conclusion, the strategy remains to buy on dips, with an ideal entry around 30.30 and a target at the technical resistance above 32.
OANDA:XAGUSDLong
by Mihai_Iacob
10
CADCHF – Potential Short Opportunity on RetestCADCHF has broken below a key support zone, indicating a shift in momentum to the downside. This zone previously acted as support and may now turn into resistance, aligning with the break-and-retest strategy. A bearish confirmation, such as rejection candles, a bearish engulfing pattern, or slowing bullish momentum, would strengthen the case for continued downside. Should this scenario play out, the next target for sellers would be around the 0.63387 level. Traders should remain patient and wait for the price to revisit the resistance zone and provide clear rejection signals before considering short positions.
Short
by TrendDiva
3
DJI - Testing Key Demand Zone – Potential Buy OpportunityThe DJI is currently trading near a key demand zone. This area aligns with previous price reactions, suggesting that buyers may step in to defend this level. The market structure indicates a potential for a bullish reversal if the demand zone holds and price action confirms support. A successful bounce from this level could lead to a move toward the 42,812.75 level, which represents a logical target for this setup. Traders should monitor for bullish confirmation signals, such as bullish engulfing candles, long lower wicks, or a breakout above short-term resistance. This setup aligns with the idea of a trend continuation from support and offers a potential opportunity for a long position. What are your thoughts on this analysis? Let me know if you agree with this setup or have alternative insights to share! Feel free to comment below!
TVC:DJILong
by DanieIM
DXY could start correcting soonThe last quarter of 2024 was exceptionally bullish for the DXY, with the price climbing from 100 to a peak around 109—a substantial 9% increase in a relatively short period. The bullish momentum has continued into the start of 2025. However, since late December, the price action has become more overlapping, which could indicate the potential for a reversal. At present, the price remains above the bullish trendline, so there are no clear reversal signals yet. That said, it’s important to monitor for a downside break. If such a scenario occurs, the index could drop toward the 106 support level.
TVC:DXYShort
by Mihai_Iacob
1
GbpUsd could correct from important supportLast week, GBP/USD saw a sharp decline, dropping over 400 pips from its recent high after briefly spiking above former support, which has now turned into resistance. The pair is currently trading at 1.2150. Although the overall trend remains strongly bearish, a short-term correction and upward move is possible. The 1.2070 level serves as key technical support, and with the psychological 1.2000 level nearby, short-term traders might find buying opportunities in this zone. If a rebound occurs, the 1.2300 level could serve as a potential target for such a trade.
Long
by Mihai_Iacob
6
GOLD - Short Setup from Resistance ZoneThe XAUUSD pair has recently broken out of the bullish channel, signaling a shift in momentum toward bearish conditions. After this breakdown, the price is currently retesting the resistance zone. This retest is a critical point for the pair, as rejection from this resistance could confirm the bearish outlook. Traders should look for bearish confirmation signals such as rejection candles, bearish engulfing patterns, or a series of lower highs to validate further downside potential. If the resistance holds, the next significant target for sellers is the $2,650.43 support level, which could act as a key demand zone. A break below this level would open the door to further declines, potentially extending the bearish trend. This setup suggests a high-risk zone for buyers and presents an opportunity for short positions if bearish confirmations are observed. Careful monitoring of price action around the retest is essential for planning entries and exits. What are your thoughts on this bearish scenario?
FX:XAUUSDShort
by TrendDiva
4
GBPCHF - Potential Buy From Key Support ZoneThe GBPCHF pair is approaching a critical demand zone, which is marked by historical price reactions and strong support levels. The current market structure suggests the potential for a reversal from this area. If buyers regain control, we could see a move higher. I anticipate that if the price confirms a rejection from the demand zone, there is a high likelihood of upward movement toward the 1.12000 level. This aligns with the expectation of trend exhaustion near this support zone. If you have any additional insights or a different perspective, feel free to share your thoughts!
Long
by DanieIM
1
Gold Outlook: Higher Lows Signal Continued Upside PotentialYesterday was a pretty volatile day for gold, with the price briefly dropping to 2615. However, bulls quickly regained control, pushing the price back above the 2635–2640 support zone and establishing a higher low in the broader trend. Currently, the price is stable above this key support level and is challenging interim resistance at 2650. A successful break above this resistance could open the door for a move toward 2680, with further upside targets at the significant 2700 level and the technical resistance at 2715. I remain bullish as long as yesterday's low at 2615 remains unbroken.
OANDA:XAUUSDLong
by Mihai_Iacob
2
Friday "NFP" Sell Signal Alert!The market has been following the trendline for the past 2-3 days. A daily price close with a Doji candle suggests indecision, while our daily bias remains bullish. However, today is Friday, and we have the NFP news event. We anticipate the market to move up by 120-130 pips, following the trendline, toward my identified resistance zone. Wait for gold to reach this resistance area before taking any action. For a bearish scenario, the target range is around 310+ pips. The market may first create a large wick during the news event before experiencing a significant drop. i'll keep this idea updated.
OANDA:XAUUSDShort
by Profit-Scalper
16
Can Silver Maintain Momentum Above 28.70?In my previous OANDA:XAGUSD analysis, I mentioned that the price appeared to be forming a head-and-shoulders pattern, with confirmation if the price broke below the 30 level. Indeed, just before Christmas, the price dropped below this critical milestone and reached a low near the 28.70 zone. However, instead of continuing toward the technical 28 support level, the price found new support at 28.70, forming a double bottom at this level. Similar to Gold, Silver began the year on a positive note, reversing upward and retesting the broken neckline level at 29.80 for the second time. Currently, the price is trading below this level. A decisive break above 30 could trigger bullish momentum, leading to a potential rally toward the 32 resistance zone. For now, I'm bullish on Silver as long as the 28.70 support zone holds.
OANDA:XAGUSDLong
by Mihai_Iacob
EURNZD - Potential Rejection at ResistanceThe EURNZD pair is approaching a significant resistance zone marked by prior price rejections. This area aligns with a key supply zone, and the market structure hints at a potential reversal. The overall context suggests that sellers may take control at this level, leading to a downward move. I anticipate that if the price shows a clear rejection from the resistance zone, the market may head lower toward the 1.83200 support level. This setup aligns with the idea of trend exhaustion near resistance. if you agree with this analysis or have any additional insights, feel free to share your thoughts in the comments!
Short
by DanieIM
Ai16Z | From Meme to Money making machineai16z is the new star in the meme token galaxy, built on the lightning fast Solana blockchain and launched on the playful daos. fun platform. With AI backing it and a cheeky nod to the a16z VC fund, this token’s got serious meme mentum. Today’s Price Check -Current Price: $1.27 (+5% in the last 24 hours) -All-Time High (ATH): $1.38 (hit on Dec 29, 2024) – just 5.86% below the peak. -Circulating Supply: 1.10 billion tokens (max supply also 1.10 billion). -24-Hour Trading Volume: A whopping $75.84 million. Market Flex ai16z is traded on 24 markets and 14 exchanges, with Gate.io leading the pack. It holds a cozy 0.04% share of the total crypto market, boasting a market cap of $1.43 billion. Oh, and word on the street? It’s on Binance’s radar for a potential listing Riding the Meme Wave Move over, SHIB, PEPE, and DOGE—ai16z is stealing the spotlight in the meme coin market rally. Its lowest price ever? A humble $0.01019 on Nov 3, 2024. Fast forward to now, and it’s up an insane 12,650% from that rock bottom price. The Whale Tale December 28 was a big day for ai16z, thanks to a crypto whale who made some serious moves. This savvy investor withdrew 10M USDC from Coinbase and snagged 13.16M ai16z tokens when they were undervalued on Dec 11. The result? In just two weeks, their $10 million investment ballooned to a jaw-dropping $15.66 million, netting a sweet $5.66 million profit. That’s the kind of whale flex you all dream about. ai16z is proving it’s more than just a meme, it’s a mover and shaker in the Solana ecosystem.
Long
by moonypto
2
Ai & OnChain Opportunities | Crypto insights for 2025How Base, Ai & Pump Fun Will Shape the Crypto Market in 2025 2024: A Milestone Year for On-Chain Growth The year 2024 may prove pivotal for onchain development, potentially rivaling the "DeFi Summer." Narrative driven investment opportunities are expected to proliferate, fueled by the widespread adoption of the “everything can be a Meme” concept and the rapid asset issuance popularized by Pump Fun. Meme projects can now launch without requiring top tier centralized exchange (CEX) listings, with market caps in the onchain space reaching approximately $1 billion. This presents significant profit opportunities for ordinary users, with toptier CEXs serving as the final stage for cashing out on-chain investments. Challenges for Established Assets Rising tensions between VCCoin and its community have led to underperformance for new assets listed on major CEXs, while older projects struggle to stay relevant. Many such projects lack motivation or fail to adapt to market changes, often adopting a passive strategy while awaiting unlock periods. Key Predictions for 2025 1. DEX/CEX Monthly Volume Ratio to Exceed 20% In December 2024, decentralized exchange (DEX) trading volumes hit a record $320 billion, marking over 200% year-over-year growth. The DEX/CEX ratio rose from 9.6% in December 2023 to 11.7%, peaking at 13.9% during the year. Continued improvements in Web3 wallets and on-chain tools, spearheaded by CEXs, along with the growing appeal of the Meme sector, are expected to accelerate user migration from CEXs to DEXs. 2. AI Agents/AI Meme Market Cap to Eclipse NFTs AI Agents integrated with tokenization have emerged as the fastest-growing narrative, with the total market cap for related tokens reaching $12 billion. Frameworks like ai16z’s Eliza and Virtuals Protocol’s Game Framework have gained dominance, enabling rapid deployment of AI Agent tokens. Virtuals Protocol’s VIRTUAL token leads the sector with a $3.5 billion market cap, bolstered by a robust ecosystem of subtokens. 3. Emergence of Vertical Launch Platforms The success of Pump Fun on Solana, a low-cost launchpad for issuing Memecoins, has inspired similar platforms across other networks. Specialized vertical platforms like vvaifu (AI Agents) and Pump Science (DeSci) are gaining traction. The expansion of the “everything can be a Meme” narrative is expected to drive demand for more niche launchpads. 4. Base Ecosystem Tokens to Debut on Binance The Base network, an Ethereum Layer 2 developed under Coinbase, is predicted to have at least five native tokens listed on Binance’s spot market. With a concentrated ecosystem led by Virtuals and Farcaster, Base is positioned as a key contender for listings. Integration with Coinbase Wallet and the potential for favorable U.S. policies could enhance its competitive edge. 5. Hyperliquid’s Spot Market to Drive Wealth Effects Hyperliquid, leveraging its HYPE token airdrops and novel asset standards (HIP1 and HIP2), is positioned to create exclusive wealth-generation opportunities. Projects like Solv Protocol and Azuki   Anime have utilized its spot listing auctions, attracting significant interest. HYPE’s value, while substantial, will benefit from increased trading volume and partnerships with exclusive projects. These projections reflect growing innovation in onchain development, with decentralized finance, AI tokenization, and specialized launchpads driving the next phase of market evolution.
Long
by moonypto
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
EurNzd could rise to 1.85On October 1st, EUR/NZD reached a local low at the psychological level of 1.75, followed by a reversal that lasted until November 1st, gaining nearly 1300 pips. A normal correction then occurred, and from mid-November, the pair started consolidating between the 1.78 and 1.80 levels. December brought a breakout above the key 1.80 level, and since then, EUR/NZD has been in a nice uptrend. As of now, the price is 1.8230, and it looks like a breakout above resistance is imminent. In this scenario, the next target for the bulls is the 1.85 level.
Long
by Mihai_Iacob